The government of Paraguay has approved a hemp oil CBD product for use as a medicine.
The government of Paraguay has approved medical marijuana treatment by cannabidiol (CBD). CBD is non-psychoactive. This decision was made by the South American country’s health department. The Dirección Nacional de Vigilancia Sanitaria is similar to FDA approval for medicines in the United States.
The products, HempMeds Real Scientific Hemp Oil-X and Real Scientific Hemp Oil Blue Label, are manufactured in San Diego, California. The company uses extracted oil from industrial hemp grown in Europe to formulate the medicines.
Raúl Elizalde, the president of HempMeds Latin America, noted in an interview with High Times that
“the registration was accelerated for humanitarian purposes. Our botanical-based products were shown to be effective when pharmaceutical products failed to adequately control seizure disorders.”
As a result, these newly registered medicines have been distributed to pharmacies and can be prescribed by doctors. The MMJ therapies are currently being used by doctors in Paraguay to treat cancer, multiple sclerosis, chronic pain, epilepsy and other neurological diseases.
The HempMeds products are formulated to contain cannabidiol (CBD) and other botanical compounds from cannabis, with little or no THC. Similarly, RSHO Blue Label contains less than 0.3% THC to comply with United States federal regulations. In addition, RSHO-X contains no measurable THC to satisfy Mexican authorities wary of the psychoactive cannabinoid.
The Government of Paraguay Approves
Dr. Stuart Titus is the CEO of Medical Marijuana Inc., the parent company of HempMeds. He said in a statement released January 9th, that the decision in Paraguay is part of a concerted effort by the company to gain access to more international markets.
“We have actively pursued getting our pipeline of botanical cannabis products registered and approved as therapeutic products in countries around the world,” he said.
The company has marked success in that endeavor in Latin America. Besides Paraguay and Mexico, HempMeds products are also available to patients in Brazil, the region’s most populous country.
“This is yet another example of the international trend of acceptance of CBD for therapeutic use. We are continually encouraged by the decisions of governments and regulators to permit the use of cannabis and CBD products. For patients suffering from multiple indications—especially where conventional medicine has had modest or limited effects,” added Dr. Titus.